Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 11/20 | 0.52 |
| ▸ | INPP5A | Q14642 | 6/20 | 0.52 |
| ▸ | INPP5B | P32019 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270559 | 1.00 | INPPL1 (0.52) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL5574731 | 0.84 | LMNA (0.34) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL1276837 | 0.82 | LMNA (0.33) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL25058821 | 0.81 | KDM4E (0.47) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL17038536 | 0.81 | INPPL1 (0.44) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL17038148 | 0.81 | KDM4E (0.47) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL29613140 | 0.81 | INPPL1 (0.52) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL224271 | 0.81 | INPPL1 (0.52) | INPPL1INPP5AINPP5BSRCKDM4E | |
| Phosphoric Acid SCHEMBL7921303 | 0.79 | INPPL1 (0.50) | INPPL1INPP5AINPP5BSRCKDM4E | |
| Benzene SCHEMBL27478938 | 0.79 | KDM4E (0.53) | INPPL1INPP5AINPP5BSRCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115746054-A | Bidentate phosphine ligand, preparation method thereof and application of bidentate phosphine ligand in catalyzing enol hydroformylation-hydrogenation reaction to prepare linear alcohol | 万华化学集团股份有限公司 | 2023-03-07 | — | — | CN | claimed |
| EP-4707404-A2 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3492919-B1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12215118-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11780863-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115746054-A | Bidentate phosphine ligand, preparation method thereof and application of bidentate phosphine ligand in catalyzing enol hydroformylation-hydrogenation reaction to prepare linear alcohol | 万华化学集团股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11365210-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-3492919-A2 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127405-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-10168336-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| EP-3111224-B1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170089911-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MEDICAL SYSTEMS, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-3111224-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015124703-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MEDICAL SYSTEMS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20070009428-A1 | Compounds and methods for enhanced delivery to disease targets | GENERAL ELECTRIC COMPANY | 2007-01-11 | — | — | US | disclosed |
| US-20070009427-A1 | Compounds and methods for enhanced delivery to disease targets | GENERAL ELECTRIC COMPANY | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
| US-20190127405-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
| US-20070009428-A1 | Compounds and methods for enhanced delivery to disease targets | SERPINA6, PAICS, FABP1 | INPPL1 2882/4885INPP5A 3311/4885INPP5B 2861/4885 |
| US-11780863-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
| US-12215118-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
| US-20070009427-A1 | Compounds and methods for enhanced delivery to disease targets | SELPLG, FABP1, PIGO | INPPL1 2402/4885INPP5A 3114/4885INPP5B 2872/4885 |
| US-20170089911-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
| US-10168336-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
| US-11365210-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | INPPL1 2299/4885INPP5A 2916/4885INPP5B 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.